Notably, cHL display a higher abundance of CD4+ TILs than DLBCL, consistent with literature [31,32,33], and further supporting the critical role of CD4+ T-cells in anti-tumor immunity in HL and as target for immunotherapy. The gene discussed is CD4; the disease is neoplasm.